Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9% to around 4-6% during up to 7 years of ...

Prostate volume and serum prostate-specific ... majority of men following initial combination therapy with the dual 5-alpha reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461-466.

Back to Healio A recent study found prior use of 5-alpha-reductase inhibitors for benign prostatic hyperplasia was associated with delayed prostate cancer diagnosis and worse prostate cancer outcomes.

Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study Use of 5-alpha-reductase ...

The impact of a positive family history on clinical and pathologic outcomes of active surveillance for prostate cancer. The BARCODE1 pilot study targeting men with increased genetic risk of developing ...

"The second class of medications, called 5 alpha-reductase inhibitors, cause the prostate to gradually shrink over time [Proscar and Avodart]. This effect may take several months to reach the ...

They treat BPH by causing the prostate’s smooth muscle to relax, allowing urine to flow freely through the urethra. 5-alpha reductase inhibitors block the production of the male sex hormone ...

These medications, such as Flomax, Rapaflo, and Cardura, work by relaxing the affected muscles around the prostate to encourage urine flow. Another type of medication is a 5-alpha reductase inhibitor.

The demand for 5-Alpha-Reductase inhibitors, such as finasteride, is driven by several factors. Firstly, these medications have shown effectiveness in reducing prostate size and alleviating ...

5-alpha reductase blockers reduce DHT levels ... It can also reduce DHT levels by 90 percent in your prostate gland, which can effectively treat androgenic alopecia and an enlarged prostate.